Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Mesocarb (Sydnocarb)

Plain-language summaryIntrigue 60 / 100

Mesocarb (sydnocarb) is a Soviet-developed stimulant with a sydnone-imine structure. It produces stimulant effects similar to amphetamine but with reportedly less abuse potential and cardiovascular stress. Used in Russia for fatigue and depression. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

38/100

Soviet-era catecholamine probe with real mechanism interest buried under an opaque, unauditable evidence base

Look, mesocarb is a weird one. It’s a Soviet-era stimulant that Western pharmacologists have almost entirely ignored, and that neglect creates both its interest and its fundamental problem as a research target. The compound class, sydnone-imines, is simply not a scaffold most Western investigators have ever worked with.

The mechanism is the interesting part. Unlike amphetamines, mesocarb doesn’t invert the dopamine or norepinephrine transporters. It drives gradual release of stored catecholamines from presynaptic terminals through a pathway that still isn’t fully characterized in English-language literature. The result is a substantially flatter stimulant curve, slower onset peaking around one to three hours, and what the Russian clinical record consistently describes as attenuated reinforcing effect relative to equivalent catecholaminergic amphetamine doses. That dissociation is genuinely worth studying. If your question is what happens when you elevate synaptic dopamine and norepinephrine without fast kinetics and without DAT inversion, mesocarb is one of the few available comparators. Thats a real question in addiction biology and in abuse-liability pharmacology, and the compound answers it in a way that methylphenidate and modafinil cant.

The evidence problem is serious. The clinical database is almost entirely Russian-language, published in Soviet and post-Soviet journals across several decades of documented medical use in ADHD, narcolepsy, asthenia, and post-stroke fatigue. Human data exists, including dose-response profiles and adverse effect characterization, but the methodological standards are opaque from any Western vantage point. A small number of English-language reviews confirm the basic pharmacological story. Replicated Western trials dont exist. So what we actually have is a compound with a plausible and interesting mechanism, real-world clinical exposure in millions of patients, and essentially no peer-reviewed evidence that survives standard scrutiny.

What mesocarb is specifically good for is as a comparative probe in catecholamine release experiments. For a lab asking how much of amphetamine’s reinforcing and cardiovascular signature comes from kinetics versus the DAT/NET inversion, mesocarb gives you an active comparator that strips out the latter. That’s a defined and legitimate use case. It isn’t broadly useful outside that framing.

Sourcing lands you in the research-chemical market. Mesocarb is not DEA-scheduled in the United States, which removes legal friction, but vendor consistency is the variable it always is in that space. We think this compound rewards the investigator willing to engage with Russian-language primary literature directly. The underlying pharmacology is real and the mechanism is legitimately differentiated. What it isn’t is a modern, well-replicated compound with an active Western research community behind it. Treat it as a narrow probe for specific mechanistic comparisons, not as a primary research target.

Novelty

40

Mechanism promise

45

In-category differentiation

42

Evidence quality

25

Translational signal

33

Research bench value

38

Rationale Mesocarb earns modest scores because the mechanism differentiation from classical amphetamines is genuine and creates real probe value, but the clinical evidence base is almost entirely Russian-language Soviet-bloc literature with methodological standards that are impossible to audit from a Western peer-review standpoint; no hard category cap applies, and it isnt DEA-scheduled.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sydnone-imine stimulant

A Soviet-developed sydnone-imine class psychostimulant marketed for fatigue and ADHD-like indications, characterized by gradual catecholamine release and modest abuse liability relative to amphetamines.

Abstract

Mesocarb (Sydnocarb; CAS 34262-84-5; molecular formula C18H18N4O2; molecular weight 322.36) is a sydnone-imine class psychostimulant developed in the Soviet Union in the 1970s and marketed in the USSR and successor states for asthenia, narcolepsy, ADHD, and post-stroke fatigue. The compound is a phenylisopropylsydnonimine and is structurally distinct from the amphetamine scaffold despite producing amphetamine-like central effects. Mechanism is gradual release of stored catecholamines (dopamine, norepinephrine) from presynaptic terminals through an indirect mechanism that does not depend on the DAT/NET inversion characteristic of amphetamines. The kinetics of release are substantially slower than amphetamine; plasma concentrations rise gradually over 1 to 3 hours after oral administration and decline over 6 to 8 hours. The slower kinetics correspond clinically to less reinforcing subjective effect, lower abuse liability, and a flatter cardiovascular profile than equivalent amphetamine doses. Mesocarb is not approved by the FDA, EMA, or any Western regulatory authority. The compound is registered as a medicine in Russia, Ukraine, Belarus, and several other former Soviet states; it is sold as a research chemical in the West. The clinical evidence base is largely Russian-language literature; published English-language reviews are sparse but credible reports describe efficacy in attention deficit, depression-related fatigue, and post-stroke cognitive impairment. Doses in clinical use are 5 to 50 mg per day in divided doses. Safety considerations include the same general cautions as other catecholaminergic stimulants (insomnia, anxiety, tachycardia, hypertension) but at attenuated rates relative to amphetamines.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-024Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Rolziracetam

Plain-language summaryIntrigue 25 / 100

Rolziracetam is a bicyclic pyrrolidinone racetam. Research compound with limited published clinical data. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundLow merit

13/100

Obscure bicyclic racetam with no characterized mechanism, no human data, and no case for prioritization

Look, rolziracetam exists primarily as a footnote in the racetam class survey. It’s a bicyclic pyrrolidinone analog, meaning someone took the familiar piracetam scaffold and fused a second ring onto it. A structurally interesting modification that could, in principle, alter conformational flexibility and receptor interactions. The problem is that “could in principle” is essentially all that’s been published.

The mechanism hasn’t been formally characterized. We presume it overlaps with piracetam pharmacology: AMPA receptor potentiation, membrane fluidity effects, calcium handling. But that’s an inference from structural class, not from data on rolziracetam itself. That’s a significant gap. Piracetam’s own mechanism took decades to partially sort out, and we’re still arguing about it. Starting that conversation for an analog with essentially no published mechanistic work puts any investigator in a difficult position before they’ve even opened a vial.

The evidence situation is bleak. No human pharmacokinetics, no Phase 1, no peer-reviewed dose-finding. The preclinical literature that does exist is sparse enough that replication across labs isn’t really a discussion you can have. Compare this to ipamorelin, BPC-157, even epitalon: compounds with thin evidence that we still consider research-grade. Rolziracetam doesn’t clear that bar. The sourcing picture isn’t reassuring either; identity confirmation by mass spectrometry is a prerequisite before any investigational use, which flags that vendor supply chains for this compound aren’t reliable enough to treat results as meaningful.

Here’s the thing: in a racetam program, you’d reach for this compound after you’ve exhausted your options with characterized analogs. Piracetam is the class reference, flawed as it is. Aniracetam has AMPA-positive allosteric data. Phenylpiracetam has human energetics signal. Oxiracetam has hippocampal work. Coluracetam has distinct high-affinity choline uptake data. Rolziracetam adds a bicyclic twist without any corresponding evidence that the twist does something useful in a biological system.

We cant point to a reason to prioritize this compound. The structural curiosity is real: bicyclic racetam scaffolds are worth understanding in the context of structure-activity relationships. But thats work for a medicinal chemistry lab running systematic analog synthesis, not an investigator building a research program around human-relevant outcomes. If someone’s doing racetam SAR work and wants to understand what the fused ring buys you mechanistically, rolziracetam has narrow value as one data point in a series. Outside that specific context, there’s no compelling pull.

The inclusion here is for completeness. The racetam class is broad, and documenting what hasn’t been done is part of understanding the landscape. That said, if your lab time and budget are finite, and they always are, this one goes to the bottom of the queue.

Novelty

20

Mechanism promise

12

In-category differentiation

10

Evidence quality

12

Translational signal

8

Research bench value

18

Rationale Mechanism is inferred by structural class association rather than any published rolziracetam-specific data; no Phase 1, no human PK, and a preclinical literature too sparse to support cross-lab replication. Differentiation from characterized racetams is entirely structural speculation with no supporting pharmacological evidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Bicyclic pyrrolidinone racetam

A bicyclic piracetam analog with sparse published literature; primarily of historical and research-chemical interest.

Abstract

Rolziracetam is a bicyclic racetam analog with sparse published literature and no clinical development record. The compound features a fused bicyclic scaffold built on the pyrrolidinone core. Mechanism is presumed to overlap with piracetam pharmacology but has not been formally characterized. The compound is occasionally available from research chemical vendors; identity confirmation by mass spectrometry is essential before any investigational use. There is no published human pharmacokinetic data, no Phase 1 safety record, and no peer-reviewed dose-finding studies. This entry is included for completeness of the racetam class survey and as a marker that “racetam” as a class label spans well-characterized compounds (piracetam, levetiracetam) and obscure analogs with thin evidence bases.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-040Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
CX-717

Plain-language summaryIntrigue 52 / 100

CX-717 is a methylsulfonyl benzoxazine ampakine investigated for ADHD and respiratory depression. The respiratory application was based on AMPA-mediated stimulation of central respiratory networks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

The furthest-advanced CX-series ampakine, with real military human data but stalled Phase 2 development

Look, CX-717 is probably the most serious compound in the CX-series to ever see human volunteers, and that matters. Most ampakines from the Cortex Pharmaceuticals pipeline stayed in rodents or at best healthy volunteer Phase 1 work. CX-717 actually made it into DoD-funded sleep deprivation trials, and the published data from those studies is real: modest but reproducible improvements in vigilance and working memory during 24-72 hour sleep deprivation windows. Turner and colleagues published those results and they held up. Thats a bar that most research chemicals in this space never clear.

The mechanism here is AMPA receptor positive allosteric modulation. Specifically, CX-717 slows AMPA receptor deactivation and desensitization, which has downstream effects on synaptic strengthening, BDNF expression, and arousal-relevant circuitry. The benzoxazine class was specifically engineered to avoid the respiratory depression issues that dogged earlier ampakines like CX-516 and CX-614. That engineering worked, and the cleaner safety profile is part of why this one made it furthest in clinical development. AMPA PAM is not a new idea in 2025, but its still a genuinely interesting mechanism for cognitive enhancement and one the field hasn’t fully cracked at the translational level.

Where things get complicated is in the so-what question. CX-717 ran Phase 2 work in adult ADHD and the results were partial at best. The compound never advanced to Phase 3 or FDA review. That stall tells you something: the effect sizes weren’t compelling enough to justify continued development at commercial scale, or there were tolerability issues at higher doses that the low-impact class designation didn’t fully solve. We don’t know the full picture because incomplete pharma clinical data is rarely published cleanly.

As a bench tool, we think CX-717 has real but specialized utility. If you’re investigating AMPA-mediated plasticity, cognitive resilience under sleep debt, or BDNF upregulation pathways, having a compound with published human PK and real Phase 2 dose data is actually useful. You’re not working blind on the translational side. But if you want to study AMPA biology more broadly, newer PAMs with better characterized profiles exist and the competitive landscape has shifted since the early Cortex Pharmaceuticals era.

Honestly, the score here reflects a compound that showed genuine promise and cleared real bars that most research chemicals never approach, but ultimately hit a ceiling. The human signal is there; the effect size isn’t paradigm-defining. It sits comfortably in the worth-knowing, worth-studying-in-the-right-context zone rather than the immediately-prioritize-this tier.

Novelty

40

Mechanism promise

60

In-category differentiation

52

Evidence quality

50

Translational signal

40

Research bench value

48

Rationale CX-717 earns credit for being the most clinically advanced benzoxazine ampakine, with published DoD sleep-deprivation human data and Phase 2 ADHD work that most CX-series compounds never approached; however, the stalled development arc, modest effect sizes in published studies, and the maturity of the AMPA PAM class hold it solidly in established-active territory rather than novel-frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylsulfonyl benzoxazine ampakine

A methylsulfonyl benzoxazine ampakine that advanced furthest of the CX-series in human trials, including military sleep deprivation studies.

Abstract

CX-717 (1-(N-methyl-N-methylsulfonyl-aminobenzoyl)pyrrolidine; CAS 412960-03-7) is a methylsulfonyl benzoxazine ampakine developed at Cortex Pharmaceuticals that advanced further in human trials than other CX-series compounds. The compound was studied by DARPA and the Department of Defense for cognitive performance maintenance during sleep deprivation in military personnel; published results showed modest but reproducible improvements in vigilance and working memory performance during 24- to 72-hour sleep deprivation. CX-717 was also studied for adult ADHD with partial Phase 2 results. The compound did not advance to FDA approval. Pharmacokinetics: plasma half-life approximately 3 to 4 hours; oral bioavailability adequate. The compound is sold as a research chemical with limited availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-057Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
PT-141 (Bremelanotide)

Plain-language summaryIntrigue 72 / 100

PT-141 (bremelanotide), sold as Vyleesi, is a synthetic peptide approved by the FDA for hypoactive sexual desire disorder in premenopausal women. It activates melanocortin receptors in the brain that regulate sexual response. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

52/100

FDA-approved MC4R agonist with real clinical validation but fading novelty and modest effect size

Look, PT-141 is a genuinely interesting compound, just not for the reasons most people think it is. The interesting part isnt the sexual function application per se, its the broader implication: that a cyclic heptapeptide hitting MC4R in the CNS can produce meaningful behavioral effects through dopaminergic and oxytocinergic downstream signaling. That mechanism story, traced from the serendipitous observation of arousal effects during early melanotan II sunless-tanning trials, is one of the more entertaining pivots in peptide pharmacology. Palatin Technologies ran with it for two decades and got an approved drug. Thats real.

The evidence base is genuinely solid by peptide standards. The RECONNECT-1 and RECONNECT-2 trials were phase 3, randomized, placebo-controlled, and they got Vyleesi through the FDA in 2019 with a 1.75 mg subcutaneous dose. On the evidence axis, PT-141 outscores most of the peptide library, which leans heavily on single-lab preclinical work. Here you have actual RCT data in humans with a replicated endpoint. The translational signal is real.

What tempers our enthusiasm is the effect size and the side-effect profile. The RECONNECT trials showed statistically significant improvements in satisfying sexual events and desire scores, but the absolute improvement was modest and the dropout-from-adverse-events number was notable, driven primarily by nausea. The FDA required a boxed warning about blood pressure changes. That limits the translational signal score from reaching the high end. We also cant ignore that flibanserin (Addyi) hit a related space via 5-HT1A agonism and 5-HT2A antagonism before PT-141 did, so the idea of a CNS-mediated HSDD treatment wasnt invented here, even if the mechanism is distinct.

On novelty, the compound has been in the literature since the late 1990s via the melanotan lineage and the MC4R mechanism in sexual behavior has been thoroughly dissected across many labs. By 2026 this isnt a fresh area of inquiry. Where PT-141 retains real bench utility is as a pharmacological probe for the melanocortin system more broadly, specifically MC4R, which sits at an interesting intersection of energy homeostasis, pain modulation, inflammation, and behavior. Researchers investigating that intersection have a clean, selective, FDA-approved probe with well-characterized PK. That matters.

We think this sits solidly in the established-active bucket. Its not a compound you’d build a research program around from scratch today, but it’s a legitimate tool if your program already touches the melanocortin axis or CNS peptide pharmacology. The evidence quality is the strongest argument for it. The novelty deficit is the strongest argument against spending your next grant cycle here.

Novelty

38

Mechanism promise

50

In-category differentiation

55

Evidence quality

62

Translational signal

60

Research bench value

50

Rationale PT-141 earns legitimacy from its 2019 FDA approval and two randomized controlled trials, but seven years post-approval the melanocortin-4 mechanism is well-characterized and the effect size data is sobering; it sits comfortably in established-active territory, differentiated from PDE5 inhibitors and flibanserin by mechanism but no longer a frontier target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Melanocortin-4 receptor agonist

A FDA-approved (2019) melanocortin receptor agonist (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, derived from melanotan II.

Abstract

Bremelanotide (Vyleesi; PT-141; CAS 189691-06-3; molecular formula C50H68N14O10; molecular weight 1025.18) is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The compound is derived from the alpha-MSH analog melanotan II by structural modification that increased selectivity toward MC4 versus MC1 (reducing the skin pigmentation activity prominent in melanotan II). PT-141 was originally developed as a sunless tanning agent before pivoting to sexual function applications when central effects were observed. Mechanism is melanocortin-4 receptor agonism in the central nervous system, with downstream effects on dopaminergic and oxytocinergic pathways implicated in sexual response. The compound is administered subcutaneously prior to anticipated sexual activity. Approved dose is 1.75 mg subcutaneous prior to use. Pharmacokinetics: plasma half-life approximately 2.7 hours; the central effect persists 4 to 6 hours after administration. Adverse events include nausea (highest frequency), hyperpigmentation with chronic use, and modest blood pressure elevation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-091Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Glycine

Plain-language summaryIntrigue 56 / 100

Glycine is the smallest amino acid, both a building block of proteins and a neurotransmitter. It functions as a co-agonist at NMDA receptors. Used as a sleep aid (3 grams before bed) and as part of GlyNAC (glycine + NAC) for longevity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

29/100

Foundational amino acid with interesting longevity angles that haven’t moved beyond rodents

Glycine is as basic as it gets. The simplest proteinogenic amino acid, it shows up everywhere in biology: glycinergic inhibitory neurotransmission, hepatic conjugation reactions, heme precursor synthesis, structural collagen content. Its ubiquity is also the problem. When evaluating a compound as a serious research target, “it does a lot of things reasonably well” isn’t a ringing endorsement. It’s a description of a nutrient.

The two angles that generate any real interest here are the methionine restriction mimetic story and the NMDA glycine-site co-agonism. We think the methionine restriction angle is genuinely interesting biology. Methionine restriction reliably extends lifespan in rodents, and the mechanism involves suppressed methionine flux through the transmethylation pathway. Glycine supplementation at 5-10 g/day can shift that flux by enhancing one-carbon transfer reactions, producing a metabolic phenotype that approximates dietary methionine restriction without actually restricting methionine intake. The Brind group published the core preclinical rationale around 2011, and subsequent work has continued to support the rodent model. The problem is that its been well over a decade and human longevity data is essentially nonexistent. This is a promising story in mice that hasnt moved.

The NMDA co-agonist angle is less exciting than it sounds. Glycine binds the modulatory glycine site on NMDA receptors, the same site targeted by more interesting compounds like D-cycloserine or GLYX-13. Bannai et al. (2012) showed 3 g before bed improved subjective sleep quality and reduced daytime sleepiness in a small Japanese cohort. Real effect, real mechanism, modest replication in subsequent work. But as a probe for NMDA biology, glycine is outclassed by D-serine, which carries roughly three-fold higher affinity at GluN2B-containing receptors, and by more selective pharmacological tools developed since. You’d use glycine here only if cost and sourcing are the binding constraints.

Differentiation is the core issue. Glycine is priced at pennies per gram, freely available from dozens of food-grade suppliers, and studied across hundreds of labs over decades. There’s no axis where it clearly bests alternatives. For NMDA research, D-serine and GLYX-13 are better probes. For longevity and methionine restriction work, alpha-ketoglutarate and caloric restriction mimetics are further along the clinical pipeline. For sleep, there are more studied interventions.

Honestly, we don’t see a compelling case for adding glycine to a serious research stack unless you’re specifically interrogating one-carbon metabolism or building a methionine restriction mimetic protocol where cost is a real constraint. Even then, the frontier work is upstream of glycine, not in it. It’s a supporting player, not a lead compound.

Novelty

18

Mechanism promise

32

In-category differentiation

18

Evidence quality

40

Translational signal

38

Research bench value

40

Rationale Glycine scores below the basic-aa cap on its own merits: the methionine restriction mimetic story is real but over a decade old with no human longevity data, the NMDA glycine-site angle is outclassed by more selective probes, and differentiation across all categories is essentially zero. Calculated overall of 29 falls under the 32 cap, so the cap doesn’t bind, but the category classification stands.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amino acid / NMDA co-agonist

The simplest amino acid with multiple biological roles including methionine restriction mimetic effects studied for lifespan extension.

Abstract

Glycine (CAS 56-40-6; molecular formula C2H5NO2; molecular weight 75.07) is the simplest amino acid, with multiple biological roles: protein synthesis, neurotransmission (inhibitory glycinergic synapses, NMDA co-agonist at the glycine modulatory site), heme synthesis (precursor to porphyrin), and as a substrate for hepatic conjugation. Glycine has been studied as a methionine restriction mimetic; methionine restriction extends lifespan in rodents, and glycine supplementation diverts methionine away from protein synthesis through enhanced one-carbon transfer reactions, producing similar metabolic phenotype to methionine restriction. The compound is also a potent NMDA glycine site co-agonist with sleep-promoting effects at 3-gram bedtime doses. Doses for sleep are 3 grams orally; doses for methionine restriction mimetic effects are 5 to 10 grams per day; the compound is exceptionally safe with rare adverse events.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-106Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
P21 (Cerebrolysin-derived peptide)

Plain-language summaryIntrigue 65 / 100

P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) developed for neuroprotection and neurogenesis. Used in research for memory and Alzheimer disease investigations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

45/100

Mechanistically coherent neurogenic peptide stuck behind a single-lab evidence wall

Look, P21 has one thing going for it that cerebrolysin itself never could: it’s an actual molecule. Seven amino acids, defined sequence, definable dose. When Khalid Iqbal’s group at the New York State Institute for Basic Research pulled this peptide out of the active fraction and pinned it to a CNTF-receptor-related mechanism driving dentate gyrus neurogenesis, that was genuinely useful work. Adult hippocampal neurogenesis is a serious research target, and having a defined peptide that demonstrably stimulates it in rodent models is not nothing.

The mechanism is what we find most interesting here. CNTF receptor signaling in the context of adult neurogenesis is a real frontier. P21 appears to operate through pathways related to the CNTF receptor complex, producing dose-dependent increases in new neuron formation in the dentate gyrus and corresponding improvements in spatial learning and memory in aged and AD-model rodents. That’s a coherent story. It’s not a trivial “more BDNF” hand-wave; theres a specific receptor angle with specific behavioral readouts, and the ciliary neurotrophic factor pathway is mechanistically distinct from the BDNF/TrkB axis that most neurogenic compounds lean on.

Here’s the problem: it’s still basically one group, one lab. Iqbal’s work on P21 spans several papers and the lab has real credibility in the AD field, but external replication is thin. We haven’t seen multi-lab confirmation of the neurogenesis effect or independent validation of the CNTF-receptor mechanism at scale. The animal models are relevant — transgenic AD mice and cognitively aging rodents are the right system for these claims — but rodent-to-human translation in neurogenesis research has historically been brutal. The dentate gyrus neurogenesis story itself is contested in humans in ways it simply isn’t in rodents.

There’s also no human data. None. No phase 1, no small-N pilot, not even a case series. For a compound with this much mechanistic specificity, thats a notable gap. Pharmacokinetics in humans are essentially unknown, and we dont know whether intranasal or subcutaneous administration delivers meaningful CNS levels in a primate brain at any practical dose.

What P21 does offer is genuine bench utility as a CNTF-pathway probe for investigators working in adult neurogenesis or AD-related cognitive biology. If you’re running hippocampal slice work or transgenic rodent behavioral studies, P21 is a more tractable tool than cerebrolysin’s poorly-defined mixture. That’s real value, just narrow. We think this sits as a solid single-lab story worth watching but not worth centering a program on until someone outside the Iqbal consortium picks it up and replicates the core findings independently.

Novelty

55

Mechanism promise

58

In-category differentiation

48

Evidence quality

28

Translational signal

30

Research bench value

42

Rationale P21 earns real marks for its defined CNTF-receptor mechanism and dentate gyrus neurogenesis signal in AD rodent models, but the evidence base is almost entirely Iqbal’s group at NY State IBR with no meaningful external replication and zero human data; single-lab preclinical only holds the overall to 45.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

CNTF-derived neurogenic peptide

A short peptide derived from a cerebrolysin fraction with documented hippocampal neurogenesis activity in animal models.

Abstract

P21 is a peptide of the sequence Ala-Asp-Asn-Phe-Val-Phe-Lys derived from the active fraction of cerebrolysin (or related neurotrophic preparations) and identified by Khalid Iqbal’s group at the New York State Institute for Basic Research. The compound stimulates neurogenesis in the dentate gyrus through a CNTF-receptor-related mechanism, producing dose-dependent improvements in spatial learning and memory in rodent models of cognitive aging and Alzheimer disease pathology. The compound has not been advanced to human clinical trials. Pharmacokinetics are poorly characterized in humans. The compound is sold as a research peptide; investigational doses parallel cerebrolysin range scaled to peptide content.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-124Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
NG2-101

Plain-language summaryIntrigue 30 / 100

NG2-101 is an investigational neurogenic peptide. Limited published research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

20/100

Vendor-marketed neurogenic peptide with no disclosed sequence, no peer-reviewed data, and no verifiable mechanism

Look, the neurogenesis research space is genuinely interesting. BDNF and NGF pathway modulation, adult hippocampal neurogenesis as a therapeutic lever, the TrkB agonism story coming out of groups like Bhanu Bhanu, Moses Bhanu at UT Southwestern, NSI-189’s serotonergic angle. There’s real science here, and we wouldn’t pretend otherwise. The problem is that NG2-101 is not a participant in that science. It’s a vendor label attached to a compound with no disclosed amino acid sequence, no published pharmacology, and no peer-reviewed characterization of any kind.

Here’s the thing about scoring a compound like this: you can’t reward proximity to an interesting class when the compound itself is a black box. We don’t know what NG2-101 actually is. The mechanism claim, BDNF or NGF mimetic-like activity on hippocampal neurogenesis, is plausible as a concept, but plausibility borrowed from established biology isn’t mechanism evidence. Without a sequence, you can’t even design a meaningful experiment around it. Without published pharmacokinetic data, you don’t know if it crosses the blood-brain barrier, what its half-life is, or whether it degrades before reaching target tissue. Those aren’t minor gaps. Thats the entire foundation of a research program.

Evidence quality is essentially zero. Not single-lab, not preliminary, not contested. There is no published primary literature to contest. Vendor-supplied efficacy claims with no institutional affiliation, no DOI, and no identifiable investigator group behind them don’t register on the evidence axis. The distinction matters: BPC-157 has one dominant lab but it’s a real lab, with identifiable authors, peer-reviewed papers, and a replicable model system. NG2-101 doesn’t even clear that bar.

Bench value follows directly. An uncharacterized compound cannot serve as a pharmacological probe because you cant control what you cant identify. If you’re asking a question about TrkB signaling, you use 7,8-DHF or a validated TrkA/TrkB antibody; if you’re looking at BDNF pathway biology, you use recombinant BDNF or LM22A-4 with established binding constants. NG2-101 offers no comparable experimental handle. Investigators running neurogenesis programs would spend more time characterizing this compound than doing science with it, and even that characterization work wouldn’t be publishable without sequence disclosure.

We’re not dismissing neurogenic peptide research. We think it’s one of the more interesting spaces in cognitive biology right now. But a vendor label isn’t a research compound, and scoring it as one would be doing a disservice to investigators who need accurate signal about where to put their bench time. Obtain analytical confirmation before any investigational use, and treat efficacy claims with proportionate skepticism.

Novelty

35

Mechanism promise

30

In-category differentiation

15

Evidence quality

8

Translational signal

8

Research bench value

12

Rationale NG2-101 scores near-floor on evidence, translational signal, and bench value because there is literally nothing to evaluate: no published sequence, no peer-reviewed characterization, and no replication outside vendor claims. The claimed neurogenesis space is legitimately interesting, which buoys novelty and mechanism slightly, but those scores reflect the concept being borrowed rather than any actual compound-level work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Investigational neurogenic peptide

An investigational peptide for hippocampal neurogenesis with limited public characterization.

Abstract

NG2-101 is a research peptide marketed for neurogenic applications with limited published characterization. The compound’s specific sequence and mechanism are not fully disclosed in peer-reviewed literature; vendor claims center on hippocampal neurogenesis effects similar to BDNF or NGF mimetics. The absence of peer-reviewed characterization is significant; investigators should treat the compound with substantial skepticism and obtain analytical confirmation of identity and purity before any investigational use. There is no formal pharmacokinetic, safety, or efficacy data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-140Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Arketamine

Plain-language summaryIntrigue 78 / 100

Arketamine is the R-enantiomer of ketamine (the other half of the racemate). Animal studies suggest the antidepressant effects may be longer-lasting than esketamine with fewer dissociative side effects. Investigated as an alternative depression treatment. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

58/100

Enantiomeric ketamine with a compelling TrkB-over-NMDA mechanism story and active phase 2 clinical development

Here’s the thing about arketamine: the pharmacology is more interesting than the name implies. Everyone knows ketamine; a lot of people now know esketamine (Spravato). R-ketamine sits in a genuinely strange position, which is lower NMDA receptor affinity than its (S)-sibling, yet rodent models consistently show more durable antidepressant effects and a reduced dissociative burden. That paradox is exactly where the interesting science lives.

The mechanism story has sharpened considerably over the last few years. Kenji Hashimoto’s lab at Chiba University built a series of papers arguing that arketamine’s antidepressant action leans harder on downstream signaling, specifically BDNF/TrkB pathway activation and mGluR modulation, than on acute NMDA channel blockade. The 2021 Casarotto et al. work in Cell added broader context: TrkB is a direct binding target for ketamine-class molecules, and the two enantiomers differ meaningfully in their TrkB-to-NMDA affinity ratio. That mechanistic wedge is what makes arketamine scientifically interesting rather than just a stereochemical footnote.

What we like here is the probe utility. If you want to dissect NMDA-dependent from TrkB-dependent antidepressant mechanisms, running parallel R versus S experiments is one of the cleaner designs available. The enantiomeric comparison opens questions that neither compound answers alone. Thats valuable even if arketamine never clears phase 3. For investigators working on NMDA receptor biology, synaptic plasticity, or rapid-acting antidepressant mechanisms, this is a tool worth having access to.

The differentiation story versus esketamine is compelling but not closed. Esketamine has FDA approval, a defined clinical niche in treatment-resistant depression and acute suicidality, and market infrastructure. Arketamine’s pitch is fewer dissociative effects plus potentially more sustained efficacy, a profile that would matter enormously for outpatient use and treatment adherence. Perception Neuroscience is running phase 2 trials. The preclinical case is solid; the human case is early and needs legs.

Evidence quality is the honest constraint. Hashimoto’s group dominates arketamine’s preclinical literature in a way that echoes the BPC-157 situation: strong signal from one sophisticated lab that needs broader independent replication. Early phase 2 human readouts are encouraging but have not yet been confirmed across multiple independent trial groups. We want to see that before the evidence score moves.

Scheduling matters for access: as a ketamine enantiomer, arketamine carries Schedule III status, which shapes institutional access and researcher infrastructure. Not a dealbreaker for programs already handling ketamine, but it narrows the field. Overall this sits in a genuinely interesting corner of depression pharmacology, and the enantiomeric probe value alone justifies attention from serious NMDA or neuroplasticity programs.

Novelty

60

Mechanism promise

72

In-category differentiation

55

Evidence quality

45

Translational signal

48

Research bench value

65

Rationale Arketamine scores well on mechanism because the enantiomeric differentiation from esketamine is pharmacologically meaningful and the TrkB/BDNF angle is supported by multi-lab work; evidence and translational scores are held back by Hashimoto-lab dominance in the preclinical literature and phase 2 data that lacks cross-group replication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

R-enantiomer NMDA antagonist

The (R)-enantiomer of ketamine, currently in clinical development for depression with reportedly more sustained antidepressant action and fewer dissociative effects.

Abstract

Arketamine (R-ketamine; CAS 33643-47-9) is the (R)-enantiomer of ketamine, currently in clinical development by Perception Neuroscience and others. The (R)-enantiomer has lower NMDA receptor affinity than the (S)-enantiomer (esketamine), but rodent data suggest more sustained antidepressant effects with reduced dissociative side effects. Phase 2 trials are ongoing. Mechanism includes NMDA modulation but with secondary mechanisms (BDNF/TrkB pathway, mGluR effects) that may underlie the differential clinical profile. Not currently FDA approved.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-172Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Astaxanthin

Plain-language summaryIntrigue 58 / 100

Astaxanthin is a red carotenoid antioxidant produced by microalgae and concentrated in salmon, krill, and other marine animals. One of the most potent natural antioxidants, with activity at lipid bilayers where vitamin E acts. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

31/100

Best-in-class carotenoid that nonetheless occupies a boring research corner with modest clinical effect sizes

Look, astaxanthin is legitimately the best carotenoid. The unique keto-carotenoid structure lets it span the phospholipid bilayer rather than just embedding in one leaflet, which gives it better membrane-level antioxidant geometry than beta-carotene, lutein, or zeaxanthin. In head-to-head in vitro radical scavenging assays it beats vitamin E by a significant margin and outperforms vitamin C handily. That part is real chemistry and we dont want to dismiss it.

Here’s the thing though: that story is old. The Haematococcus pluvialis sourcing pipeline is mature, the NRF2 activation and NF-kB suppression mechanisms are thoroughly described, and the compound has been in clinical studies since at least the early 2000s. Nobody in a serious lab is discovering something new about astaxanthin’s mechanism. If you want to run NRF2 pathway studies, sulforaphane is a more pharmacologically specific probe. If you want to study mitochondrial ROS, there are mitochondria-targeted antioxidants like MitoQ or SS-31 with more interesting translational stories.

The clinical evidence is where the score really takes a hit. Most of the human RCT data is industry-funded (AstaReal dominates the published trial landscape), small-N, and producing effect sizes that are statistically present but clinically unimpressive. The skin photoprotection literature has the most consistent signal but the effects are modest. Exercise recovery data is mixed; the studies that show benefit tend to be short, in untrained subjects, and not replicated cleanly outside the funding consortium. Cardiovascular endpoints have some early signal but nothing that would make a cardiologist change their practice.

We think astaxanthin is worth having in a library as a reference compound for carotenoid and membrane antioxidant research, and it has a niche in photoprotection biology. But if a bench investigator came to us asking whether this was worth centering a research program on, we’d steer them elsewhere. The mechanism isnt novel, the differentiation is real but confined to a category that doesnt excite the field anymore, and the human translational signal has been disappointing relative to the preclinical promise that got everyone interested a decade ago.

Sourcing is fine, the AstaReal and Algatechnologies supply chains are clean and well-characterized, and the compound is chemically stable under reasonable storage conditions. It has value in any stack or study where you want a well-characterized oral antioxidant reference, and the BBB penetration is genuine. For a narrow question in carotenoid or skin biology it can still earn its place on the bench. Just not a high-priority standalone target in 2026.

Novelty

20

Mechanism promise

28

In-category differentiation

40

Evidence quality

38

Translational signal

32

Research bench value

28

Rationale Astaxanthin earns genuine differentiation within carotenoids via its membrane-spanning xanthophyll structure and superior ROS quenching, but the antioxidant/NRF2/NF-kB mechanism space is crowded and the clinical signal across all indications remains modest-N and industry-funded. Novelty is low, bench probe value is real but limited, and the overall lands just under the 35 OTC-food/herb cap without needing it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Carotenoid antioxidant

A red carotenoid pigment from Haematococcus pluvialis algae characterized by potent antioxidant activity and high oral bioavailability.

Abstract

Astaxanthin (CAS 472-61-7; molecular formula C40H52O4; molecular weight 596.84) is a red carotenoid pigment produced by Haematococcus pluvialis (the algal source of most commercial astaxanthin) and present in seafood (salmon, krill, shrimp). The compound is one of the most potent natural antioxidants, exceeding the radical-quenching capacity of vitamin C, vitamin E, and beta-carotene in many in vitro assays. Pharmacology includes direct radical scavenging, NRF2 pathway activation, and anti-inflammatory effects through NF-kB inhibition. Clinical applications include skin photoprotection (modest evidence), cardiovascular function, and exercise recovery. Doses are typically 4 to 12 mg per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-189Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Citalopram

Plain-language summaryIntrigue 60 / 100

Citalopram (Celexa) is a Danish-developed SSRI from H. Lundbeck, approved in Europe in 1989 and in the US in 1998. It is sold as a 50/50 mix of two mirror-image molecules; only one of those mirror images, the (S) form, actually does the serotonin-blocking work. The other is mostly inert and may even slow the active half down. That insight led Lundbeck to repackage the active half on its own as escitalopram. Citalopram is among the most selective SSRIs for serotonin over other targets, which gives it a clean side-effect profile but does carry a dose-dependent risk of QT interval prolongation on the heart tracing, prompting the FDA to cap the daily dose at 40 mg in 2011. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Canonical SERT-selective reference probe; mature mechanism, real but narrow bench utility, superseded clinically by its own enantiomer

Honestly, citalopram earns a place in the library primarily as a pharmacological reference tool rather than as a research frontier. Approved by the FDA in 1998 and in Europe a decade earlier, it’s been around long enough that the mechanism literature is essentially complete: SERT inhibition, the CYP2C19/3A4/2D6 metabolic fingerprint, the QTc story, the downstream 5-HT receptor adaptations. Thats not a knock on the science; it’s just what a mature compound looks like.

What keeps it relevant is the selectivity profile. We’ve seen a lot of SSRIs, but citalopram’s greater-than-1000-fold selectivity for SERT over NET and DAT is genuinely exceptional in the class. If you’re running a mechanistic experiment and need to isolate serotonin transporter pharmacology without confounding adrenergic or dopaminergic effects, citalopram is your reference standard. That selectivity makes it a real probe tool in certain experimental designs, specifically anything probing pure serotonergic neurotransmission where norepinephrine leak would contaminate the read.

Here’s the thing about the racemate though: the (S)-enantiomer carries essentially all SERT activity, while the (R)-enantiomer is largely inactive but may attenuate (S)-enantiomer binding through an allosteric SERT interaction. This makes citalopram mildly interesting from a stereochemistry standpoint. You have a situation where one enantiomer acts as an allosteric modulator of the other’s primary target binding. Some groups have used this as a model system for studying allosteric SERT interactions — that’s about as novel as citalopram gets mechanistically in 2026, and it’s still a modest signal.

The QTc boxed warning issued by the FDA in 2011, which cut the maximum recommended dose from 60 to 40 mg, reflects a hERG channel interaction that any serious SSRI structure-activity program has to account for. For in vitro and cell-based work this is largely irrelevant, but worth knowing if you’re using it as a comparator in cardiac safety assays or ion channel screening.

We don’t think citalopram is worth prioritizing as a primary research target right now. The mechanism is fully characterized, the major clinical questions are answered, and escitalopram has replaced it in most contexts where you specifically want clean SERT activity. Where it remains genuinely useful: as a reference compound in SERT pharmacology work, in structure-activity relationship studies of the phthalane scaffold, and as a racemic SSRI comparator where you actually want the stereospecificity complexity in the assay design. The evidence base is massive and high quality — thats a real strength. But from a novelty and frontier standpoint, you’re not discovering new biology here. Use it as a tool; dont build a primary research program around it.

Novelty

15

Mechanism promise

20

In-category differentiation

42

Evidence quality

88

Translational signal

78

Research bench value

65

Rationale Citalopram’s exceptional SERT selectivity (>1000-fold over NET/DAT) preserves genuine probe value for serotonin transporter biology, but novelty and mechanism scores are floor-level for a fully characterized 1989 compound. The racemic/enantiomer story adds mild mechanistic texture, but the evidence and translational axes reward an approved drug with decades of RCT data, pulling the overall above the purely mature-workhorse range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective serotonin reuptake inhibitor

A racemic phthalane SSRI; the most selective for SERT over NET in clinical use.

Abstract

Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 59729-33-8; molecular formula C20H21FN2O; molecular weight 324.39) is a bicyclic phthalane SSRI developed at H. Lundbeck in Denmark and approved in Europe in 1989 and by the FDA in 1998 under the trade name Celexa. The compound is sold as the racemate; the (S)-enantiomer (escitalopram) accounts for essentially all SERT inhibitory activity, while the (R)-enantiomer is largely inactive but may attenuate the (S)-enantiomer’s binding through allosteric SERT interaction. SERT affinity ((S)-enantiomer): Ki approximately 1 nM; selectivity over NET and DAT exceeds 1000-fold, making citalopram the most selective SSRI in clinical use. Plasma half-life is 33 to 37 hours; hepatic metabolism via CYP2C19, CYP3A4, and CYP2D6 produces minimally active metabolites. The compound is associated with dose-dependent QTc prolongation (FDA boxed warning issued 2011), with the maximum recommended dose reduced from 60 mg to 40 mg as a result. Used as the canonical selective SERT inhibitor in mechanism studies and as a reference compound in SSRI structure-activity work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-204Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 62 63 64 65 66 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.